


"LCVs to outweigh medium & heavy commercial vehicles in FY13"

Sluggish economic scenario posed strain on the CV demand in FY13

Slowing down economic growth and escalating inflationary pressure since the second half of the last fiscal has shrinked the average consumer spending significantly. The M&HCV goods carrier (GC) segment especially multi-axle vehicles and tractor trailer sub-segments has bore a significant brunt as the demand for this segment dropped by a considerable 18 per cent during first half of FY13. Further, regulatory bottlenecks hovering around mining industry across key states have also considerably affected the demand for tippers.




Source: CARE Research and Society of Indian Automobile Manufacturers (SIAM)

...LCV GC continues to remain the mainstay

The LCV GC segment which is dominated by small commercial vehicles (SCV) and pickup trucks segment continued to witness healthy growth scenario even in the challenging environment. During H1FY13 period, this segment has managed to post a growth of around 20 per cent that has been mainly driven by strong demand from SCV sub-segment. Healthy redistribution demand coupled with growth in non-discretionary expenditure (especially FMCG, pharmaceuticals, etc) has aided demand for this segment. The increase in the product offerings in small commercial vehicle (SCV) segment due to frequent model launches (For example M&M 'Maxximo mini truck', Tata Motors 'Super Ace' and Ashok Leyland 'Dost' are recent entrants) has led many small transport operators to replace their three wheelers with more efficient SCV. Further, CV manufacturers have also started focusing on expanding their reach in semi urban and rural areas to market their SCVs that has not only helped in enhancing the sales but also provided cushion from the uncertainties of softening in demand from urban markets.








Source: CARE Research and Society of Indian Automobile Manufacturers (SIAM)

CV finance - Still remains an alluring prospect

Inspite of tough market condition surrounding the CV industry, CV finance market still remains an attractive proposition for the financers. CARE Research believes, even though the new CV finance market has impacted owing to the sharp slide observed in M&HCV segment in the current fiscal, strong demand from LCVs has provided some respite to the financers. Further, healthy demand scenario that was observed in CV market during last one decade has resulted in a considerable pile up of CV stock. As per CARE Research estimates around 38 per cent of the overall CV stock lies between the age bracket of 5-12 years which is considered to be a target market for used CV finance. Off-late financers have started tapping small transport operators from tier II and tier III cities and semi-urban areas, which has consolidated the growth prospect of the used CV finance industry significantly. CARE Research estimates used CV finance would manage to post a healthy rise of around 10-11 per cent in FY13.

Chart: Estimated age wise Commercial vehicle population breakup in FY13



Source: CARE Research



Domestic market to witness 5-6 per cent growth in FY13

CARE Research estimates the domestic CV industry to grow by 5-6 per cent in FY13. CARE Research believes, economic scenario will continue to remain gloomy atleast for the next 8-10 months & M&HCV GC sub-segment will bear a significant brunt. Nevertheless, healthy rise in demand from LCV GC would help in negating the slowdown by some extent as it expected to exhibit strong growth in FY13. On the other hand increased demand from STUs and corporate buying combined with government initiatives to improve public transport infrastructure will fuel the PC demand.

Contact:

Revati Kasture Head - CARE Research revati.kasture@careratings.com

Vishal Srivastav Manager

vishal.srivastav@careratings.com

This report is prepared by CARE Research, a division of Credit Analysis & REsearch Limited [CARE]. CARE Research has taken utmost care to ensure accuracy and objectivity while developing this report based on information available in public domain. However, neither the accuracy nor completeness of information contained in this report is guaranteed. CARE Research operates independently of ratings division and this report does not contain any confidential information obtained by ratings division, which they may have obtained in the regular course of operations. The opinion expressed in this report cannot be compared to the rating assigned to the company within this industry by the ratings division. The opinion expressed is also not a recommendation to buy, sell or hold an instrument.

CARE Research is not responsible for any errors or omissions in analysis/inferences/views or for results obtained from the use of information contained in this report and especially states that CARE (including all divisions) has no financial liability whatsoever to the user of this report. This report is for the information of the intended recipients only and no part of this report may be published or reproduced in any form without prior written permission of CARE Research.

Credit Analysis and Research Limited proposes, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus ("DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the website of SEBI at www.sebi.gov.in as well as on the websites of the Book Running Lead Managers at www.investmentbank.kotak.com, www.dspml.com, www.edelcap.com, www.icicisecurities.com, www.idbicapital.com, and www.sbicaps.com. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" of the DRHP.

This press release is not for publication or distribution to persons in the United States, and is not an offer for sale within the United States of any equity shares or any other security of Credit Analysis & Research Ltd. Securities of Credit Analysis & Research Ltd., including its equity shares, may not be offered or sold in the United States absent registration under U.S. securities laws or unless exempt from registration under such laws.